

P&T Motion History
Estrogens – Hormone Replacement Therapy

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>Oral Estrogens 17-beta estradiol estradiol valerate conjugated equine estrogen synthetic conjugated estrogen esterified estrogen estropipate conjugated estrogens/ bazedoxifene</p> <p>Transdermal Estrogens 17-beta estradiol</p> <ul style="list-style-type: none"> • estradiol extended-release transdermal patch • estradiol 0.1% transdermal gel <p>estradiol transdermal spray</p> <p>Vaginal Cream 17-beta estradiol conjugated equine estrogen synthetic conjugated estrogens</p>	<p>After considering the evidence of safety, efficacy and special populations, I move that the drugs included in the following tables are efficacious and have no differences in efficacy identified in special populations for the indication of menopausal symptoms and can be subject to therapeutic interchange within route of administration and subclass (oral estrogens, oral estrogen-progestin combinations, transdermal estrogens, transdermal estrogen-progestin combinations, topical estrogen products) in the Washington preferred drug list. There is insufficient evidence available to compare the relative safety of the estrogen products at this time. The Committee recommends that practitioners prescribe the lowest effective dose for shortest duration of treatment for the particular estrogen product prescribed.</p>	<p>April 19, 2017</p>	<p>Yes Johnson Sanderson</p>	<p>Yes Johnson Figueroa</p>	<p>Passed unanimous</p>